ARID1A and urinary bladder carcinoma: To assess the prevalence of ARID1A mutations in bladder cancer, we performed in silico mutation analysis via cBioPortal (http://www.cbioportal.org/), using the Memorial Sloan Kettering Cancer Center bladder cancer sequencing data set and The Cancer Genome Atlas (TCGA) data set (2).